Safeguarding pluripotent stem cells for cell therapy with a non-viral, non-integrating episomal suicide construct

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7261-7271

  Zhao, Qingguo ^a   Lu, Baisong ^a   George, Sunil K ^a   Yoo, James J ^a   Atala, Anthony ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cell culture; DNA; Genetic engineering; Stem cell; Transplantation

Indexed keywords

CELL SOURCES; CELL THERAPY; CELL TRANSPLANTATION; DIFFERENTIATED CELLS; GANCICLOVIR; IN-VITRO; IN-VIVO; INSERTIONAL MUTAGENESIS; NEGATIVE SELECTION; NONVIRAL; PLASMID DNA; PLURIPOTENT STEM CELLS; POSITION EFFECT; TUMOR FORMATION; VIRAL VECTORS;

BIOMOLECULES; CELL CULTURE; DNA; GENETIC ENGINEERING; TRANSPLANTATION (SURGICAL); TUMORS;

STEM CELLS;

GANCICLOVIR; OCTAMER TRANSCRIPTION FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4A; PLASMID DNA; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; EPISOME; FEMALE; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE VECTOR; MATRIX ATTACHMENT REGION; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUICIDE GENE; THYMIDINE KINASE GENE;

ANIMALS; CELL TRANSPLANTATION; CHO CELLS; CRICETINAE; DNA; FEMALE; FLOW CYTOMETRY; GANCICLOVIR; GENE SILENCING; GENETIC ENGINEERING; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; MUTAGENESIS; PLASMIDS; PLURIPOTENT STEM CELLS; STEM CELLS; TRANSGENES;

EID: 84864314840     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.038     Document Type: Article

References (49)

1. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., et al. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
2. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
3. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
4. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
5. Hentze H., Soong P.L., Wang S.T., Phillips B.W., Putti T.C., Dunn N.R. Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res 2009, 2:198-210.
6. Xu X.Q., Zweigerdt R., Soo S.Y., Ngoh Z.X., Tham S.C., Wang S.T., et al. Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy 2008, 10:376-389.
7. Duinsbergen D., Salvatori D., Eriksson M., Mikkers H. Tumors originating from induced pluripotent stem cells and methods for their prevention. Ann N Y Acad Sci 2009, 1176:197-204.
8. Brawley C., Matunis E. Regeneration of male germline stem cells by spermatogonial dedifferentiation in vivo. Science 2004, 304:1331-1334.
9. Kiuru M., Boyer J.L., O'Connor T.P., Crystal R.G. Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 2009, 4:289-300.
10. Schuldiner M., Itskovitz-Eldor J., Benvenisty N. Selective ablation of human embryonic stem cells expressing a "suicide" gene. Stem Cells 2003, 21:257-265.
11. Cao F., Lin S., Xie X., Ray P., Patel M., Zhang X., et al. In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation 2006, 113:1005-1014.
12. Jung J., Hackett N.R., Pergolizzi R.G., Pierre-Destine L., Krause A., Crystal R.G. Ablation of tumor-derived stem cells transplanted to the central nervous system by genetic modification of embryonic stem cells with a suicide gene. Hum Gene Ther 2007, 18:1182-1192.
13. Naujok O., Kaldrack J., Taivankhuu T., Jorns A., Lenzen S. Selective removal of undifferentiated embryonic stem cells from differentiation cultures through HSV1 thymidine kinase and ganciclovir treatment. Stem Cell Rev 2010, 6:450-461.
14. Hara A., Aoki H., Taguchi A., Niwa M., Yamada Y., Kunisada T., et al. Neuron-like differentiation and selective ablation of undifferentiated embryonic stem cells containing suicide gene with Oct-4 promoter. Stem Cells Dev 2008, 17:619-627.
15. Cheng F., Ke Q., Chen F., Cai B., Gao Y., Ye C., et al. Protecting against wayward human induced pluripotent stem cells with a suicide gene. Biomaterials 2012, 33:3195-3204.
16. Hewitt Z., Priddle H., Thomson A.J., Wojtacha D., McWhir J. Ablation of undifferentiated human embryonic stem cells: exploiting innate immunity against the Gal alpha1-3Galbeta1-4GlcNAc-R (alpha-Gal) epitope. Stem Cells 2007, 25:10-18.
17. Wang Y., Yang D., Song L., Li T., Yang J., Zhang X., et al. Mifepristone-inducible caspase-1 expression in mouse embryonic stem cells eliminates tumor formation but spares differentiated cells in vitro and in vivo. Stem Cells 2012, 30:169-179.
18. Nusse R., van Ooyen A., Cox D., Fung Y.K., Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984, 307:131-136.
19. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther 2005, 16:1241-1246.
20. Sadelain M., Papapetrou E.P., Bushman F.D. Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer 2012, 12:51-58.
21. Piechaczek C., Fetzer C., Baiker A., Bode J., Lipps H.J. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res 1999, 27:426-428.
22. Stehle I.M., Scinteie M.F., Baiker A., Jenke A.C., Lipps H.J. Exploiting a minimal system to study the epigenetic control of DNA replication: the interplay between transcription and replication. Chromosome Res 2003, 11:413-421.
23. Manzini S., Vargiolu A., Stehle I.M., Bacci M.L., Cerrito M.G., Giovannoni R., et al. Genetically modified pigs produced with a nonviral episomal vector. Proc Natl Acad Sci U S A 2006, 103:17672-17677.
24. Jenke A.C., Stehle I.M., Herrmann F., Eisenberger T., Baiker A., Bode J., et al. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci U S A 2004, 101:11322-11327.
25. Schaarschmidt D., Baltin J., Stehle I.M., Lipps H.J., Knippers R. An episomal mammalian replicon: sequence-independent binding of the origin recognition complex. EMBO J 2004, 23:191-201.
26. Baiker A., Maercker C., Piechaczek C., Schmidt S.B., Bode J., Benham C., et al. Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix. Nat Cell Biol 2000, 2:182-184.
27. Mielke C., Kohwi Y., Kohwi-Shigematsu T., Bode J. Hierarchical binding of DNA fragments derived from scaffold-attached regions: correlation of properties in vitro and function in vivo. Biochemistry 1990, 29:7475-7485.
28. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 1967, 26:365-369.
29. Zhao Q., Wang J., Zhang Y., Kou Z., Liu S., Gao S. Generation of histocompatible androgenetic embryonic stem cells using spermatogenic cells. Stem Cells 2010, 28:229-239.
30. Prokhorova T.A., Harkness L.M., Frandsen U., Ditzel N., Schroder H.D., Burns J.S., et al. Teratoma formation by human embryonic stem cells is site dependent and enhanced by the presence of Matrigel. Stem Cells Dev 2009, 18:47-54.
31. Euhus D.M., Hudd C., LaRegina M.C., Johnson F.E. Tumor measurement in the nude mouse. J Surg Oncol 1986, 31:229-234.
32. Norrman K., Fischer Y., Bonnamy B., Wolfhagen Sand F., Ravassard P., Semb H. Quantitative comparison of constitutive promoters in human ES cells. PLoS One 2010, 5:e12413.
33. Prosch S., Stein J., Staak K., Liebenthal C., Volk H.D., Kruger D.H. Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler 1996, 377:195-201.
34. Argyros O., Wong S.P., Niceta M., Waddington S.N., Howe S.J., Coutelle C., et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther 2008, 15:1593-1605.
35. Leight E.R., Sugden B. Establishment of an oriP replicon is dependent upon an infrequent, epigenetic event. Mol Cell Biol 2001, 21:4149-4161.
36. Stehle I.M., Postberg J., Rupprecht S., Cremer T., Jackson D.A., Lipps H.J. Establishment and mitotic stability of an extra-chromosomal mammalian replicon. BMC Cell Biol 2007, 8:33.
37. Teshima S., Shimosato Y., Hirohashi S., Tome Y., Hayashi I., Kanazawa H., et al. Four new human germ cell tumor cell lines. Lab Invest 1988, 59:328-336.
38. Damjanov I., Horvat B., Gibas Z. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest 1993, 68:220-232.
39. Lee J., Kim H.K., Rho J.Y., Han Y.M., Kim J. The human OCT-4 isoforms differ in their ability to confer self-renewal. J Biol Chem 2006, 281:33554-33565.
40. Amariglio N., Hirshberg A., Scheithauer B.W., Cohen Y., Loewenthal R., Trakhtenbrot L., et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009, 6:e1000029.
41. Humme S., Reisbach G., Feederle R., Delecluse H.J., Bousset K., Hammerschmidt W., et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci U S A 2003, 100:10989-10994.
42. Kievit E., Bershad E., Ng E., Sethna P., Dev I., Lawrence T.S., et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999, 59:1417-1421.
43. Straathof K.C., Pule M.A., Yotnda P., Dotti G., Vanin E.F., Brenner M.K., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105:4247-4254.
44. Argyros O., Wong S.P., Fedonidis C., Tolmachov O., Waddington S.N., Howe S.J., et al. Development of S/MAR minicircles for enhanced and persistent transgene expression in the mouse liver. J Mol Med (Berl) 2011, 89:515-529.
45. Dachs G.U., Hunt M.A., Syddall S., Singleton D.C., Patterson A.V. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009, 14:4517-4545.
46. Li S., Tokuyama T., Yamamoto J., Koide M., Yokota N., Namba H. Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene. Oncology 2005, 69:503-508.
47. Folger K.R., Wong E.A., Wahl G., Capecchi M.R. Patterns of integration of DNA microinjected into cultured mammalian cells: evidence for homologous recombination between injected plasmid DNA molecules. Mol Cell Biol 1982, 2:1372-1387.
48. Frank O., Rudolph C., Heberlein C., von Neuhoff N., Schrock E., Schambach A., et al. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 2004, 104:3543-3549.
49. Dang Q., Auten J., Plavec I. Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. J Virol 2000, 74:2671-2678.